• 11832 - Alexis
    Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial
    Andrew F. Alexis, Matthew Zirwas, Michael Bukhalo, Zoe D. Draelos, James Del Rosso, Angela Y. Moore, Edward Lain, Laura K. Ferris, Fran E. Cook-Bolden, Bruce Binkowitz, Saori Kato, Scott Snyder, David H. Chu, Patrick Burnett, David R. Berk
    Poster Abstract

  • 11907 - Bagel
    Improvement in Disease Severity and Quality of Life in Patients With Atopic Dermatitis Treated With Dupilumab for up to 18 Months: Real-World Data From the PROSE Registry
    Jerry Bagel, Gil Yosipovitch, David M. Pariser, Robert Y. Lin, Zafer Ozturk, Andrew Korotzer
    Poster Abstract

  • 11866 - Berman
    EFFICACY OF TIRBANIBULINOINTMENT 1% ACROSS DIFFERENT PATIENT POPULATIONS: POOLED RESULTS FROM TWO PHASE 3 STUDIES
    Brian Berman, Adrià Gual, Ayman Grada, Emilio Fumero, Laura Padullés, Francisco Hernández
    Poster Abstract

  • 11897 - Berman
    COMPLETE CLEARANCE OF ACTINIC KERATOSIS OBSERVED FROM DAY 8 OF TIRBANIBULIN TREATMENT, ALONG WITH GOOD TOLERABILITY: POST-HOC ANALYSIS OF TWO PHASE 3 STUDIES
    Brian Berman, Girish Gupta, Laura Padullés, Francisco Hernández
    Poster Abstract

  • 11837 - Bhatia
    Psoriasis-related work productivity improvement from a phase 4 real-world study interim analysis of tildrakizumab in patients with moderate to severe psoriasis
    Neal Bhatia, Jayme Heim, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, J Gabriel Vasquez
    Poster Abstract

  • 11908 - Bissonnette
    Dupilumab Treatment Normalizes Skin Barrier Function and Improves Clinical and Patient-Reported Outcomes in Patients With Atopic Dermatitis
    Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, Amy Praestgaard, Noah A. Levit, Ana B. Rossi, Annie Zhang
    Poster Abstract

  • 11901 - Blauvelt
    Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
    Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, Bruce Strober, Andreas Pinter, Jose-Manuel Carrascosa, Paolo Gisondi, Jonathan Bleier, Cynthia Madden, Delphine Deherder, Natalie Nunez Gomez, Richard B. Warren
    Abstract

  • 11853 - Blauvelt
    Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
    A. Blauvelt, K.C. Duffin, N. Magnolo, J. Weisman, M. Ståhle, D. Wilsmann-Theis, M. Wang, K. Wixted, B. Szilagyi, L. Puig
    Poster Abstract

  • 11910 - Blauvelt
    Long-Term Efficacy of Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis (AD): Results From an Open-Label Extension (OLE) Trial up to 4 years
    Andrew Blauvelt, Benjamin Lockshin, Jacob P. Thyssen, Ryszard Galus, Charles Lynde, Jing Xiao, Noah A. Levit, Ainara Rodríguez Marco, Arsalan Shabbir
    Poster Abstract

  • 11916 - Blauvelt
    Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
    Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Alexa B Kimball
    Abstract

  • 11833 - Blauvelt
    Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial
    Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe D. Draelos, Janet DuBois, Seth B. Forman, Melinda Gooderham, Scott T. Guenthner, Adelaide A. Hebert, Edward Lain, Angela Y. Moore, Kim A. Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David R. Berk, David H. Chu
    Poster Abstract

  • 11899 - Blauvelt
    Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE and BE RADIANT)
    Andrew Blauvelt, Kristina Callis Duffin, Nina Magnolo, Jamie Weisman, Mona Ståhle, Dagmar Wilsmann-Theis, Maggie Wang, Krista Wixted, Balint Szilagyi, Luis Puig
    Abstract

  • 11836 - Blauvelt
    Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
    Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, Bruce Strober, Andreas Pinter, Jose-Manuel Carrascosa, Paolo Gisondi, Jonathan Bleier, Cynthia Madden, Delphine Deherder, Natalie Nunez Gomez, Richard B. Warren
    Poster

  • 11818 - Blauvelt
    Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
    Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Alexa B Kimball
    Poster Abstract

  • 11842 - Cork
    Long-Term Efficacy of Abrocitinib After Initial Successful Treatment in Patients With Atopic Dermatitis
    Michael J. Cork, Kim A. Papp, Mette Deleuran, Andrew E. Pink, Kristian Reich, Pinaki Biswas, Gary Chan, Claire Feeney, Wing Sin Chiu, Rowena M. Randall
    Poster Abstract

  • 11864 - Del Rosso
    Management of Truncal Acne With Oral Sarecycline: Pooled Results From Two Phase-3 Clinical Trials
    James Q. Del Rosso, Linda Stein Gold, Hilary Baldwin, Julie C. Harper, Joshua Zeichner, Sabine Obagi, Emmy Graber, Xochitl Jimenez, Francisco Hernandez Vicente, Raidah Salem, Ayman Grada
    Poster Abstract

  • 11913 - Dickerson
    Personalized Medicine for Psoriasis Biologic Treatment
    Tobin J. Dickerson, PhD, Byung-In Lee, PhD, Paul Montgomery III, MS, Stephen Boyd, BS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD
    Poster Abstract

  • 11911 - Dickerson
    Personalized Medicine for Psoriasis Biologic Treatment
    Tobin J. Dickerson, PhD, Byung-In Lee, PhD, Paul Montgomery III, MS, Stephen Boyd, BS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD
    Poster Abstract

  • 11922 - DiRuggiero
    Long-term Efficacy and Safety in Participants Who Achieved Skin Clearance in an Open-label Study of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion
    Douglas DiRuggiero, DMSc, PA-C; Mark G. Lebwohl, MD2; Jerry Bagel, MD; Cula N. Svidzinski, MD; Abby Jacobson, MS, PA-C
    Poster Abstract

  • 11921 - DiRuggiero
    Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption
    Douglas DiRuggiero, April Armstrong, Brian Keegan, George Han, Abby Jacobson
    Poster Abstract